  (a) Submission
    (1) In general
       A sponsor of a drug that has entered into an agreement with the Secretary to conduct a postmarketing study of a drug shall submit to the Secretary, within 1 year after the approval of such drug and annually thereafter until the study is completed or terminated, a report of the progress of the study or the reasons for the failure of the sponsor to conduct the study. The report shall be submitted in such form as is prescribed by the Secretary in regulations issued by the Secretary.
    (2) Agreements prior to effective date
       Any agreement entered into between the Secretary and a sponsor of a drug, prior to November 21, 1997, to conduct a postmarketing study of a drug shall be subject to the requirements of paragraph (1). An initial report for such an agreement shall be submitted within 6 months after the date of the issuance of the regulations under paragraph (1).
  (b) Consideration of information as public information
     Any information pertaining to a report described in subsection (a) of this section shall be considered to be public information to the extent that the information is necessary–
    (1) to identify the sponsor; and
    (2) to establish the status of a study described in subsection (a) of this section and the reasons, if any, for any failure to carry out the study.
  (c) Status of studies and reports
     The Secretary shall annually develop and publish in the Federal Register a report that provides information on the status of the postmarketing studies–
    (1) that sponsors have entered into agreements to conduct; and
    (2) for which reports have been submitted under subsection (a)(1) of this section.
